EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

RETRACTED: Heterogeneous Longitudinal Antibody Responses to Covid-19 mRNA Vaccination

Suzanne M de la Monte iD, Christine Long, Nicole Szczepanski, Christopher Griffin, Amanda Fitzgerald, Kimberle Chapin

Clinical Pathology · 2021-01 · 14

DOI: 10.1177/2632010x211049255 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pathology, online erschienen am 07.10.2021. Verfasst von Suzanne M de la Monte und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pathology & Laboratory Medicine Service, Providence VA Medical Center, Providence, RI, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Public health measures to stem the coronavirus disease 2019 (COVID-19) pandemic are challenged by social, economic, health status, and cultural disparities that facilitate disease transmission and amplify its severity. Prior pre-clinical biomedical technologic advances in nucleic acid-based vaccination enabled unprecedented speed of conceptualization, development, production, and widespread distribution of mRNA vaccines that target SARS-CoV-2's Spike (S) protein. DESIGN: Twenty-five female and male volunteer fulltime employees at the Providence VA Medical Center participated in this study to examine longitudinal antibody responses to the Moderna mRNA-1273 vaccine. IgM-S and IgG-S were measured in serum using the Abbott IgM-S-Qualitative and IgG2-S-Quantitative chemiluminescent assays. RESULTS: Peak IgM responses after Vaccine Dose #1 were delayed in 6 (24%) and absent in 7 (28%) participants. IgG2-S peak responses primarily occurred 40 to 44 days after Vaccine Dose #1, which was also 11 to 14 days after Vaccine Dose #2. However, subgroups exhibited Strong (n = 6; 24%), Normal (n = 13; 52%), or Weak (n = 6; 24%) peak level responses that differed significantly from each other (P < .005 or better). The post-peak IgG2-S levels declined progressively, and within 6 months reached the mean level measured 1 month after Vaccine Dose #1. Weak responders exhibited persistently low levels of IgG2-S. Variability in vaccine responsiveness was unrelated to age or gender. CONCLUSION: Host responses to SARS-CoV-2-Spike mRNA vaccines vary in magnitude, duration and occurrence. This study raises concern about the lack of vaccine protection in as many as 8% of otherwise normal people, and the need for open dialog about future re-boosting requirements to ensure long-lasting immunity via mRNA vaccination versus natural infection.

Schlagwörter

Stichwörter der Autor:innen

COVID-19Spike proteinVeterans Administrationimmune responsemRNA vaccine

Autor:innen und Institutionen

  • Pathology & Laboratory Medicine Service, Providence VA Medical Center, Providence, RI, USA.
  • The Alpert Medical School of Brown University, Providence, RI, USA.

ORCID-Profile: Suzanne M de la Monte

Zitieren

APA

de la Monte, S. M., Long, C., Szczepanski, N., Griffin, C., Fitzgerald, A., & Chapin, K. (2021). RETRACTED: Heterogeneous Longitudinal Antibody Responses to Covid-19 mRNA Vaccination. Clinical Pathology, 14. https://doi.org/10.1177/2632010x211049255

Vancouver

de la Monte SM, Long C, Szczepanski N, Griffin C, Fitzgerald A, Chapin K. RETRACTED: Heterogeneous Longitudinal Antibody Responses to Covid-19 mRNA Vaccination. Clinical Pathology. 2021;14. doi:10.1177/2632010x211049255

BibTeX
@article{delaMonte2021,
  author = {de la Monte, Suzanne M and Long, Christine and Szczepanski, Nicole and Griffin, Christopher and Fitzgerald, Amanda and Chapin, Kimberle},
  title = {RETRACTED: Heterogeneous Longitudinal Antibody Responses to Covid-19 mRNA Vaccination},
  journal = {Clinical Pathology},
  year = {2021},
  volume = {14},
  doi = {10.1177/2632010x211049255}
}
Kostenlos starten →